Article Sidebar

PDF (Tiếng Việt)
Published: 2025-09-20
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52163/yhc.v66i5.3097
Issue
Vol. 66 No. 5
Section
Articles
How to Cite
Hoàng, L. B., Phương, P. T. M., Anh, T. T. V., Hoa, P. Q., Hà, V. T., Nguyệt, V. M., Hiền, Đỗ T. T., & Lan, P. T. (2025). 13. EFFICACY OF TOPICAL TACROLIMUS 0.03% IN THE TREATMENT OF FACIAL PITYRIASIS ALBA AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY. Vietnam Journal of Community Medicine, 66(5). https://doi.org/10.52163/yhc.v66i5.3097

13. EFFICACY OF TOPICAL TACROLIMUS 0.03% IN THE TREATMENT OF FACIAL PITYRIASIS ALBA AT THE NATIONAL HOSPITAL OF DERMATOLOGY AND VENEREOLOGY

Le Ba Hoang1, Pham Thi Minh Phuong1,2, Tran Thi Van Anh3, Pham Quynh Hoa3, Vu Thai Ha1,2, Vu Minh Nguyet1,2, Do Thi Thu Hien1,2, Pham Thi Lan1,2
1 Ha Noi Medical University
2 National Hospital of Dermatology and Venereology
3 National Hospital of Dermatology and Venereology -

Main Article Content

Abstract

Objective: To evaluate the clinical outcomes of treating facial pityriasis alba with topical Tacrolimus 0.03% at the National Hospital of Dermatology and Venereology from September 2024 to August 2025.


Subjects and methods: A clinical trial (interventional study with pre-post comparison and a control group) was conducted on 60 patients diagnosed with facial pityriasis alba. The intervention group (n = 30) received topical Tacrolimus 0.03%, while the control group (n = 30) was treated with topical Desonide 0.05%. The duration of treatment was 8 weeks.


Results: After 8 weeks, the mean pigmentation index in the Tacrolimus group increased significantly from 59.37 to 156.72 Melanin unit, compared to an increase from 61.78 to 114.92 Melanin unit in the Desonide group (p < 0.001). Regarding lesion size, the proportion of patients achieving good to very good response was 73.3% in the Tacrolimus group, significantly higher than 16.7% in the Desonide group (p < 0.001). Adverse effects in the Tacrolimus group were mainly itching, stinging and mild burning (13.33%). No participants discontinued treatment due to adverse effects.


Conclusion: Topical Tacrolimus 0.03% demonstrates significant efficacy in improving pigmentation and reducing lesion size in patients with facial pityriasis alba, with good tolerability and minimal side effects. It represents a safe and effective alternative to topical corticosteroids, especially for sensitive areas such as the face.

Article Details

Keywords

Pityriasis alba, Tacrolimus 0.03%, Desonide 0.05%.

References

[1] Bao Y, Chang L, Zhang W. Advances in the diagnosis and treatment of pityriasis alba. Int J Dermatol Venereol, 2015, 41, 228-229.
[2] Moreno-Cruz B, Torres‐Álvarez B, Hernández‐Blanco D et al. Double-Blind, Placebo-Controlled, Randomized Study Comparing 0.0003% Calcitriol with 0.1% Tacrolimus Ointments for the Treatment of Endemic Pityriasis Alba. Dermatol Res Pract, 2012: 303275. doi: 10.1155/2012/303275.
[3] Rigopoulos D, Gregoriou S, Charissi C et al. Tacrolimus ointment 0.1% in pityriasis alba: an open-label, randomized, placebo-controlled study. Br J Dermatol, 2006, 155 (1), 152-155.
[4] Zhai J, Gu J, Yuan J et al. Tacrolimus in the treatment of ocular diseases. BioDrugs Clin Immunother Biopharm Gene Ther, 2011, 25 (2), 89-103.
[5] Abdel-Wahab H, Ragaie M.H. Pityriasis alba: toward an effective treatment. J Dermatol Treat, 2021, 33, 2285-2289.
[6] Castanedo-Cazares J.P, Lárraga-Piñones G, Ehnis-Pérez A et al. Topical niacinamide 4% and Desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol, 2013, 6, p. 29-36.
[7] Sepaskhah M, Sadat M.S, Pakshir K et al. Comparative efficacy of topical application of Tacrolimus and clotrimazole in the treatment of pityriasis versicolor: A single blind, randomised clinical trial. Mycoses, 2017, 60, 338-342.
[8] Liu J, Shi L, Wang X et al. Tacrolimus 0.03% ointment treatment in exfoliative cheilitis: a randomised controlled clinical trial and monitoring blood concentration. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol, 2020, 50 (2): 251-259.